Features include very common findings: Palpitations and Premature atrial contractions; and common findings: Permanent atrial fibrillation, Prolonged QTc interval, Paroxysmal atrial fibrillation, and Prolonged PR interval. 7 total HPO annotations.

KCNA5 encodes potassium voltage-gated channel subfamily A member 5 (613 aa). Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes. Highest expression in Artery Aorta (82.6 TPM) and Artery Tibial (81.8 TPM).

Atrial fibrillation, familial, 7 is associated with mutations in the KCNA5 gene on chromosome 12.

The KCNA5 protein participates in KCNA5 tetramer:Class III (KCNA5) antiarrhythmics, Class III (KCNA5) antiarrhythmics bind KCNA5 tetramers, and Phase 3 - rapid repolarisation pathways.

KCNA5 is classified as a druggable target (Cell Surface, Druggable Genome, and Ion Channel categories) with score 3.5.

Genetic testing for KCNA5 is available. Testing is considered confirmatory for diagnosis.

Biomarker and diagnostic research for atrial fibrillation, familial, 7 has been reported in the published literature.

Phenotype severity distribution: 2 very common features, 4 common features.

No clinical trials have been registered for atrial fibrillation, familial, 7.

294 publications have been identified in PubMed for atrial fibrillation, familial, 7. Kisho has analyzed 216 by research type. Research spans Clinical Trial Publication (38%), Epidemiology / Natural History (32%), and Diagnostic / Biomarker (10%).